Announcement

Moderna’s Hail Mary

This series explores how the vaccine company Moderna was surreptitiously rescued from imminent collapse through public-private collusion that culminated in the extreme regulatory interventions of the Covid-19 era. These regulatory interventions allowed Moderna to circumnavigate the normal trials for safety and efficacy that its products routinely failed prior to a pandemic being declared.

Latest
3 Articles
Jul 03, 2024 The WHO: Building a Permanent Pandemic Market
The WHO: Building a Permanent Pandemic Market

Facing a wave of patent cliffs, Big Pharma is betting on risky biotech. The WHO’s revised pandemic treaty, shaped by its private funders, would build a permanent market for this biotech despite its past regulatory challenges.

Max Jones
Oct 28, 2021 COVID-19: Moderna Gets Its Miracle
COVID-19: Moderna Gets Its Miracle

COVID-19 erased the regulatory and trial-related hurdles that Moderna could never surmount before. Yet, how did Moderna know that COVID-19 would create those conditions months before anyone else?

Whitney Webb
Oct 07, 2021 Moderna: A Company “In Need Of A Hail Mary”
Moderna: A Company “In Need Of A Hail Mary”

Before COVID-19, Moderna looked like another Theranos: secretive, losing top staff, no product after nine years, a patent fight over its delivery system and toxicity so severe it dropped all multi-dose drugs. Part 1 shows how close it was to collapse, and why that matters for boosters.

Whitney Webb
Your link has expired. Please request a new one.
Your link has expired. Please request a new one.
Your link has expired. Please request a new one.
Great! You've successfully signed up.
Great! You've successfully signed up.
Welcome back! You've successfully signed in.
Success! You now have access to additional content.